Thursday, September 25, 2014

Rexahn (RNN) receives orphan drug status for lead compound

Rexahn announced they received orphan drug status from the FDA for it's lead compound targeting pancreatic cancer.  The stock is up over 7% in afternoon trading which is typical for such a release but the reality is orphan drug status is worthless if the drug isn't approved.  I'd sell on the uptick and buyback when reality sets back in.

Rexahn receives orphan drug status for lead compound


No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com